18.10.2011 • NewsJob Cutspharma industrypatent cliff

AstraZeneca to Cut 400 U.S. Jobs

AstraZeneca has announced plans to cut about 400 employees in its U.S. commercial operations, citing a need to reduce costs. The company said the jobs are mainly at its U.S. headquarters in Wilmington, Del., and some field-based, non-sales roles. The company has about 14,400 employees in North America. About 70 of the estimated positions to be eliminated will come from existing vacancies, leaving about 330 current workers affected by the cuts, said spokesman Tony Jewell. The specific jobs targeted haven't been identified yet. All decisions will be finalized by early December.

"The changes will enable the company to compete in a challenging environment, including pricing pressures and the continuing growth of generics medicines," the company said in a press release.

Several of AstraZeneca's best-selling drugs face the loss of patent expiration in coming years.

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.